drugset / Trial / NCT04214717

Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor

NCT04214717

Unknown 60 enrolled Yantai Yuhuangding Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Combinations of Dendritic cell-activated cytokine-induced killer cell (DC-CIK) With chemotherapy treatment may enhance the immune response and stop cancer cells from growing.

Timeline

Start
2019-12-31
Primary completion
2023-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject DC-CIK Cell therapy

Indications